Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?

Subsets of patients with non-small cell lung cancer respond remarkably well to small molecule tyrosine kinase inhibitors (TKI) specific for epidermal growth factor receptor (EGFR) such as gefitinib or erlotinib. In 2004, it was found that EGFR mutations occurring in the kinase domain are strongly as...

Descripción completa

Detalles Bibliográficos
Autores principales: Uramoto, H, Mitsudomi, T
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360106/
https://www.ncbi.nlm.nih.gov/pubmed/17325698
http://dx.doi.org/10.1038/sj.bjc.6603665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360106/
https://www.ncbi.nlm.nih.gov/pubmed/17325698
http://dx.doi.org/10.1038/sj.bjc.6603665

Ejemplares similares